Oncogene signal transduction inhibitors from medicinal plants

In Vivo

Volumn 10, Issue 2, 1996, Pages 185-190

  Chang, Ching Jer ^a   Ashendel, Curtis L ^a   Geahlen, Robert L ^a   Mclaughlin, Jerry L ^a   Waters, David J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Medicinal plants; Oncogenes; Signal transduction inhibitors; Tyrosine kinase

Indexed keywords

ANTHRAQUINONE; EMODIN; FLAVONOID; PROTEIN KINASE; PROTEIN TYROSINE KINASE; STILBENE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ONCOGENE; MALIGNANT TRANSFORMATION; MEDICINAL PLANT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0030053296     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Grever MR, Shepartz SA, Chabner BA: The National Cancer Institute: Cancer drug discovery and development program, Semin Oncol 19: 622-638; 1993.
2. Suffness M, Pezzuto JM: Assays related to cancer drug discovery: Methods Plant Biochem 6: 71-133, 1991.
3. Suffness M, Newman DJ, Snader K: Discovery and development of antineoplastic agents from natural sources, Bioorg Marine Chem 3: 131-167, 1989.
4. Johnson RK, Hertzberg RP: Mechanism-based discovery of anticancer agents, Ann Repts Med Chem 25: 129-140, 1990.
5. Workman P: New anticancer drug design based on advances in molecular oncology, Semin Cancer Biol 3: 329-427, 1992.
6. Kerr DJ, Workman P: "Molecular Targets for Cancer Chemotherapy" CRC Press, Boca Raton, FL, 1994.
7. Kurjan J, Taylor BL: "Signal Transduction," Academic Press, New York, NY, 1993.
8. Weinberg RA: Oncogenes and the Molecular Origins of Cancer", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
9. Hesketh R: "The Oncogene Handbook," Academic Press, New York, NY, 1994.
10. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff, S: "Oncogene and signal transduction" Cell 64: 281-302, 1991.
11. Dobrusin EM, Fry DW: "Protein-tyrosine kinase and cancer," Ann Repts Med Chem 27: 169-178, 1993.
12. Kellie S: "Tyrosine Kinase and Neoplastic Transformation," RG Landes, Co, Austin, TX, 1994.
13. Hardie G and Hanks S: "The Protein Kinase Facts Book-II: Protein-Tyrosine kinase," Academic Press, New York, 1995.
14. Fantle WJ, Johnson DE, Williams LE: "Signaling by receptor tyrosine kinase," Ann Rev Biochem. 62: 453-481, 1993.
15. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity, Cell 61: 203-212, 1990.
16. Carpenter G: "Receptor tyrosine kinase substrate: src homology domains and signal transduction" FASEB 6: 3283-3289, 1992.
17. Chang Cj, Geahlen RL: "Protein-tyrosine kinase inhibition: Mechanism-based discovery of antitumor agents," J Nat Prod 55: 1529-1560, 1992.
18. Burke Jr TR: "Protein-tyrosine kinase inhibitors," Drugs of the Future 17: 119-131, 1992.
19. Casenellie JE: "Protein kinase inhibitors: Probe for the function of protein phosphorylation" Adv Pharmacol 22: 167-205, 1991.
20. Inoue M, Kishimoto A, Takai Y, Nishizuka Y: "Studies on a cyclic nucleotide independent protein kinase and its proenzyme in mammalian tissues. II" J Biol Chem 252: 7610-7616, 1977.
21. Takai Y, Kishimoto A, Inoue M, Nishizuka Y: "Studies on a cyclic nucleotide independent protein kinase and its proenzyme in mammalian tissues. I Purification and characterization of an active enzyme from bovine cerebellum" J Biol Chem 252: 7603-7609, 1977.
22. Hardie G and Hanks S: "The Protein Kinase Facts Book-I: Protein Serine Kinases," Academic press, New York, 1995.
23. Nishizuka Y: "The role of protein kinase C in cell surface signal transduction and tumor promotion," Nature 308: 693-695, 1984.
24. Berridge MJ, Irvine RF: "Inositol phosphate, a novel second messenger in cellular signal transduction" Nature 312: 315-321, 1984.
25. Nishizuka Y: "Studies and perspectives of protein kinase C" Science 233: 305-12, 1986.
26. Basu A: "The potential of protein kinase C as a target for anticancer treatment" Pharmac Ther 59: 257-280, 1993.
27. Gescher A: 'Towards selective pharmacological modulation of protein kinase C-opportunity for the development of novel antineoplastic agents" Br J Cancer 66: 10-19, 1992.
28. Jayasuriya H, Koonchanok N, Geahlen RL, McLaughlin JL, Chang Cj: "Emodin: A protein tyrosine kinase inhibitor from Polygonum cuspidatum" J Nat Prod 55: 696-698, 1992.
29. Boyd M: Status of the NCI preclinical antitumor drug discovery screen, Updates of Principles and Practice of Oncology" (Ed: DeVita Jr, VT; Hellman, S.; Rosenberg, SA) 3: 1-12, 1989.
30. Satoh T, Nakofuku M, Kaziro Y: "Function of ras as a molecular switch in signal transduction" J Biol Chem 267: 24149-24152, 1992.
31. Gibbs JB, Marshall MS, Scolnick EM, Dixon RAF, Vogel US: "Modulation of guanine nucleotides bound to ras in NIH 3T3 cells by oncogenes, growth factors, and the GTPase activating protein" J Biol Chem 265: 20437-20442, 1990.
32. Chan TCK, Chang Cj, Koonchanok NM, Geahlen RL: "Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor" Biochem Biophys Res Commun 193: 1152-1158, 1993.
33. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen" Nature 312: 513-516, 1984.
34. Hung MC, Schechter AT, Chevray PYM, Stern DF, Weinberg RA: "Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles" Proc Nat Acad Sci USA 83: 261-264, 1986.
35. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: "Studies of the HER-2/neu protooncogene in human breast and ovarian cancer" Science 244: 707-712, 1989.
36. Seshadri R, Matthew C, Dobrovic A, Horsfall DJ: "The significance of oncogene amplification in primary breast cancer" Int J Cancer 43: 270-273, 1989.
37. Van de Vijver MJ, Peterse JL, Mooi W, Wisman P, Lomans J, Dalesio O, Nusse R: "Neu-protein overexpression in breast cancer associated with comedo-type ductal carcinoma in site and limited prognostic value in stage II breast cancer" New Engl J Med 319: 1239-1245, 1988.
38. Muller WJ, Sinn E, Pateengale PK, Wallace R, Leder P: "Induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene" Cell 54: 105-115, 1988.
39. Udziak RM, Schlessinger J, Ullrich A: "Increased expression of the putative growth factor p185 HER-2 cause transformation and tumorgenesis of NIH cells" Proc Nat Acad Sci USA 84: 7159-7163, 1987.
40. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller W.J: "Mammary tumor expressing the neu proto-oncogene possess elevated C-src tyrosine kinase activity" Mol Cell Biol 14: 735-743, 1994.
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: "Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene" Science 235: 177-182, 1987.
42. Zhang L, Chang Cj, Bacus SS, Hung MC: "Suppressed transformation and induced differentiation of HER-2/neu overexpressing breast cancer cells by emodin" Cancer Res 55: 3890-3896, 1995.
43. Jayatilake GS, Jayasuriya H, Lee ES, Koonchanok NM, Geahlen RL, Ashendel CL, McLaughlin JL, Chang Cj: "Kinase inhibitors from Polygonum cuspidatum" J Nat Prod 56: 1805-1810, 1993.
44. Thakkar K, Geahlen RL, Cushman M: "Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol" J Med Chem 36: 2950-2955, 1993.
45. Geahlen RL, McLaughlin JL: "Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor" Biochem Biophys Res Commun 165: 241-245, 1989.
46. Hsu Hy: "Treating Cancer with Chinese Herbs" Oriental Healing Art Institute, Los Angeles, CA, 220, 1982.
47. Abou-Shoer M, Ma G, Li X, Koonchanok NM, Geahlen RL, Chang Cj: "Flavonoids from Koelreuteria henryi and other sources as protein-tyrosine kinase inhibitors" J Nat Prod 56: 967-969, 1993.